Medical Doctor Program year 2023 Reported 2021–2023 Source: CMS Open Payments, 2026 publication

Shamim Malik

Psychiatry Dumas, AR Medical Doctor

NPI 1518909605 CMS profile 250692

Delta Memorial Hospital, 811 Highway 65 South, Dumas, AR 71639

Open in the dashboard

General payments

$256

12 records reported · program years 2021–2023

Research payments

$0

Paid to them · None reported · program years 2021–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Shamim Malik of Dumas, AR is reported in the CMS Open Payments database as having received $256 across 12 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 48th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $43 2
2022 General $153 7
2021 General $59 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shamim Malik
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Shamim Malik were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Shamim Malik Psychiatry median Middle half National median
2019 $0 $184 $59–$605 $163
2020 $0 $119 $36–$372 $114
2021 $59 $143 $43–$576 $132
2022 $153 $153 $50–$590 $149
2023 $43 $170 $56–$651 $160
2024 $0 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2021–2023
  1. Alkermes, Inc. $85 2 payments
  2. AbbVie, Inc. $58 3 payments
  3. Indivior Inc. $36 2 payments
  4. Janssen Pharmaceuticals, Inc $28 2 payments
  5. Neurocrine Biosciences, Inc. $26 2 payments
  6. Vanda Pharmaceuticals Inc. $22 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2023
  1. Food and Beverage $256 12 payments
Products named General payments · program years 2021–2023
  1. LYBALVI Cns $85 2 payments
  2. LYBALVI Cns $85 2 payments
  3. LYBALVI Cns $85 2 payments
  4. LYBALVI Cns $85 2 payments
  5. VRAYLAR $58 3 payments
  6. PERSERIS $36 2 payments
  7. INVEGA SUSTENNA $28 2 payments
  8. INGREZZA $26 2 payments
  9. FANAPT $22 1 payment
  10. HETLIOZ $22 1 payment
  11. Other $14 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

675

Median for Psychiatry: 574

Drug cost

$6,864

Median for Psychiatry: $27,624

Branded share of claims

15.4%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Quetiapine Fumarate Generic 71 $1,039
Buspirone Hcl Generic 72 $903
Bupropion Xl Bupropion Hcl Brand 75 $784
Chlorpromazine Hcl Generic 12 $588
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 12 $518
Clonazepam Generic 59 $428
Bupropion Hcl Generic 39 $406
Lamotrigine Generic 62 $404
Hydroxyzine Pamoate Generic 16 $361
Alprazolam Generic 99 $337

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Records

12 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record